Group items tagged

The late stage studies of Bayer's oncology drug, Alpharadin are impressive to say the least. Designed for the treatment of prostate cancer that spreads to the bones, the drug is able to extend life of late-stage patients while minimizing damage to healthy tissue.

As the first new Lupus drug to debut in the last half-of-a-century, Benlysta has the potential to be something special. Reception of the drug from doctors has been lukewarm thus far, but with many other treatments associated with severe potential side effects, Benlysta may be a blockbuster nonetheless.

Not only do companies have the potential to achieve what Novavax was able to under the right circumstances, but the industry is also full of big mergers and acquisitions. Early-stage companies develop clinical trial pipelines. Larger companies may then target these smaller firms as buyout candidates. For instance, Merck (NYSE: MRK) bought cancer drug research company VelosBio Inc. from Pappas Capital and other investors for $2.75 billion. Gilead Sciences (NASDAQ: GILD) picked up Immunomedics for $21 billion to gain access to a breast cancer treatment, Trodelvy. The list goes on. In this article, we'll look at a few current and former biotech penny stocks that have continued demonstrating strength in the stock market in 2021.

This article discusses a handful of penny stocks with exposure to potential Alzheimer's disease treatments. The bullish sympathy trend has come to light following late-breaking news on Tuesday that Biogen (NASDAQ: BIIB) and Eisai Co.'s experimental Alzheimer's drug significantly slowed the progression of the disease in a large study. The 18-month, Phase 3 study of 1,800 patients tested the treatment on early-stage Alzheimer's patients. 4 more Alzheimer's stocks to watch